How Many Seres Therapeutics, Inc. (NASDAQ:MCRB)’s Analysts Are Bearish?

September 30, 2018 - By Jason Dias

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 2 analysts covering Seres Therapeutics (NASDAQ:MCRB), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Seres Therapeutics had 2 analyst reports since May 10, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, May 10 by Cantor Fitzgerald. As per Friday, August 3, the company rating was downgraded by Bank of America. Below is a list of Seres Therapeutics, Inc. (NASDAQ:MCRB) latest ratings and price target changes.

03/08/2018 Broker: Bank of America Old Rating: Neutral New Rating: Underperform Downgrade
10/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0000 Maintain

The stock increased 0.13% or $0.01 during the last trading session, reaching $7.59. About 32,630 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 47.52% since September 30, 2017 and is downtrending. It has underperformed by 63.14% the S&P500.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $309.64 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

Another recent and important Seres Therapeutics, Inc. (NASDAQ:MCRB) news was published by which published an article titled: “Seres Therapeutics (MCRB) Appoints Meryl Zausner to Board” on September 04, 2018.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: